Firdapse (amifampridine)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Initial request: 3 months Maintenance therapy: 12 months (1 year)

Medications	Quantity Limit
Firdapse (amifampridine)	May be subject to quantity limit

APPROVAL CRITERIA

Initial requests for Firdapse (amifampridine) may be approved if the following criteria are met:

I. Individual has a diagnosis of Lambert-Eaton myasthenic syndrome; **AND**
II. Documentation is provided that diagnosis has been confirmed by one of the following:
    A. Presence of anti-P/Q-type voltage-gated calcium channel (VGCC) antibodies; **OR**
    B. Characteristic electromyography findings using nerve conduction tests, repetitive nerve stimulation (RNS), exercise testing, or single fiber electromyography (SFEMG).

Maintenance therapy requests for Firdapse (amifampridine) may be approved if the following criteria are met:

I. Documentation is provided showing objective evidence that individual achieved and sustained meaningful improvement in muscle strength.

Requests for Firdapse (amifampridine) may **not** be approved for the following:

I. Individual has a history of seizures; **OR**
II. Individual is using in combination with compounded form of 3,4 diaminopyridine.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2021. URL: http://www.clinicalpharmacology.com. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: August 12, 2021.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.